Sophie Visvikis-Siest

List of Publications by Year
in descending order

290 papers	34,390 citations	22153 59 h-index	4015 176 g-index
313 all docs	313 docs citations	313 times ranked	51587 citing authors

#	Article	IF	Citations
1	Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128Â·9 million children, adolescents, and adults. Lancet, The, 2017, 390, 2627-2642.	13.7	5,010
2	Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19Â·2 million participants. Lancet, The, 2016, 387, 1377-1396.	13.7	3,941
3	Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4Â·4 million participants. Lancet, The, 2016, 387, 1513-1530.	13.7	2,842
4	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010, 42, 937-948.	21.4	2,634
5	New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature Genetics, 2010, 42, 105-116.	21.4	1,982
6	Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19Â·1 million participants. Lancet, The, 2017, 389, 37-55.	13.7	1,667
7	Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, The, 2021, 398, 957-980.	13.7	1,289
8	The Lin28/let-7 Axis Regulates Glucose Metabolism. Cell, 2011, 147, 81-94.	28.9	812
9	Genome-Wide Association Analysis Identifies Variants Associated with Nonalcoholic Fatty Liver Disease That Have Distinct Effects on Metabolic Traits. PLoS Genetics, 2011, 7, e1001324.	3.5	796
10	Causal Relationship between Obesity and Vitamin D Status: Bi-Directional Mendelian Randomization Analysis of Multiple Cohorts. PLoS Medicine, 2013, 10, e1001383.	8.4	753
11	Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations. Nature Genetics, 2009, 41, 157-159.	21.4	585
12	A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nature Genetics, 2009, 41, 89-94.	21.4	540
13	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nature Genetics, 2011, 43, 1131-1138.	21.4	501
14	Rising rural body-mass index is the main driver of the global obesity epidemic in adults. Nature, 2019, 569, 260-264.	27.8	469
15	Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 Individuals. PLoS Genetics, 2012, 8, e1002607.	3.5	419
16	Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature, 2011, 478, 97-102.	27.8	394
17	Genome-Wide Association Identifies Nine Common Variants Associated With Fasting Proinsulin Levels and Provides New Insights Into the Pathophysiology of Type 2 Diabetes. Diabetes, 2011, 60, 2624-2634.	0.6	335
18	Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. American Journal of Human Genetics, 2018, 103, 691-706.	6.2	326

#	Article	IF	Citations
19	Genome-Wide Association for Abdominal Subcutaneous and Visceral Adipose Reveals a Novel Locus for Visceral Fat in Women. PLoS Genetics, 2012, 8, e1002695.	3.5	245
20	Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants. Lancet, The, 2020, 396, 1511-1524.	13.7	219
21	Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimerâ€™s diseaseâ˜†. Neurobiology of Aging, 2000, 21, 27-30.	3.1	217
22	Low copy number of the salivary amylase gene predisposes to obesity. Nature Genetics, 2014, 46, 492-497.	21.4	214
23	Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Human Molecular Genetics, 2012, 21, 5385-5394.	2.9	210
24	The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. American Journal of Medical Genetics Part A, 1987, 27, 567-582.	2.4	204
25	A Genome-Wide Association Search for Type 2 Diabetes Genes in African Americans. PLoS ONE, 2012, 7, e29202.	2.5	197
26	A Multilocus Genotyping Assay for Candidate Markers of Cardiovascular Disease Risk. Genome Research, 1999, 9, 936-949.	5.5	193
27	Intimaâ€“media thickness and diameter of carotid and femoral arteries in children, adolescents and adults from the Stanislas cohort. Journal of Hypertension, 1998, 16, 1593-1602.	0.5	170
28	Increased Levels of Apolipoprotein D in Cerebrospinal Fluid and Hippocampus of Alzheimer's Patients. Journal of Neurochemistry, 1998, 71, 1643-1650.	3.9	154
29	Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331â€ˆ288 participants. Lancet Diabetes and Endocrinology,the, 2015, 3, 624-637.	11.4	139
30	Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020, 582, 73-77.	27.8	138
31	IL-6, TNF-Î± and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis, 2003, 170, 277-283.	0.8	137
32	Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis, 2000, 152, 475-488.	0.8	132
33	Objectives, Design and Recruitment of a Familial and Longitudinal Cohort for Studying Gene-Environment Interactions in the Field of Cardiovascular Risk: The Stanislas Cohort. Clinical Chemistry and Laboratory Medicine, 1998, 36, 35-42.	2.3	130
34	Interactions of Dietary Whole-Grain Intake With Fasting Glucose- and Insulin-Related Genetic Loci in Individuals of European Descent: A meta-analysis of 14 cohort studies. Diabetes Care, 2010, 33, 2684-2691.	8.6	127
35	Childhood Obesity Is Associated with Shorter Leukocyte Telomere Length. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1500-1505.	3.6	127
36	Metabolic Determinants Are Much More Important Than Genetic Polymorphisms in Determining the PAI-1 Activity and Antigen Plasma Concentrations. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 84-91.	2.4	123

#	Article	IF	Citations
37	Association of Genetic Loci With Glucose Levels in Childhood and Adolescence. Diabetes, 2011, 60, 1805-1812.	0.6	103
38	Genetics strongly determines the wall thickness of the left and right carotid arteries. Human Genetics, 1998, 103, 183-188.	3.8	97
39	Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Letters, 1998, 425, 225-228.	2.8	97
40	Genetic determinants of blood pressure regulation. Journal of Hypertension, 2005, 23, 2127-2143.	0.5	94
41	Prevalence of Loss-of-Function FTO Mutations in Lean and Obese Individuals. Diabetes, 2010, 59, 311-318.	0.6	93
42	Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nature Communications, 2021, 12, 24.	12.8	87
43	Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. European Journal of Human Genetics, 2001, 9, 780-786.	2.8	86
44	Mining the Human Phenome Using Allelic Scores That Index Biological Intermediates. PLoS Genetics, 2013, 9, e1003919.	3.5	84
45	Rapid spectrophotometric method for serum glutathione S-transferases activity. Clinica Chimica Acta, 2002, 326, 131-142.	1.1	81
46	Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. British Journal of Haematology, 2005, 128, 91-99.	2.5	80
47	Transcription Factor and Drug-Metabolizing Enzyme Gene Expression in Lymphocytes from Healthy Human Subjects. Drug Metabolism and Disposition, 2008, 36, 182-189.	3.3	80
48	LEPR gene polymorphisms: associations with overweight, fat mass and response to diet in women. European Journal of Clinical Investigation, 2001, 31, 398-404.	3.4	79
49	Growing Significance of Myeloperoxidase in Non-infectious Diseases. Clinical Chemistry and Laboratory Medicine, 2002, 40, 2-8.	2.3	78
50	Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: the Stanislas study. Atherosclerosis, 2004, 172, 299-308.	0.8	78
51	High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity. European Journal of Human Genetics, 2002, 10, 553-561.	2.8	75
52	The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. European Journal of Human Genetics, 2002, 10, 841-850.	2.8	75
53	Human cytochrome P450 epoxygenases: Variability in expression and role in inflammation-related disorders. , 2014, 144, 134-161.		74
54	Identification of cis - and trans -Acting Genetic Variants Explaining Up to Half the Variation in Circulating Vascular Endothelial Growth Factor Levels. Circulation Research, 2011, 109, 554-563.	4.5	72

#	Article	IF	Citations
55	Biological variations and genetic reference values for apolipoprotein E serum concentrations: results from the STANISLAS cohort study. Clinical Chemistry, 1998, 44, 957-965.	3.2	70
56	Apolipoprotein E Polymorphism and Serum Concentration in Alzheimer's Disease in Nine European Centres: the ApoEurope Study. Clinical Chemistry and Laboratory Medicine, 2000, 38, 721-730.	2.3	70
57	Biological variations, genetic polymorphisms and familial resemblance of TNF-Î± and IL-6 concentrations: STANISLAS cohort. European Journal of Human Genetics, 2005, 13, 109-117.	2.8	70
58	Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. European Journal of Human Genetics, 2002, 10, 715-723.	2.8	67
59	Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. International Journal of Epidemiology, 2018, 47, 872-883i.	1.9	65
60	Dairy product consumption, calcium intakes, and metabolic syndromeâ€“related factors over 5 years in the STANISLAS study. Nutrition, 2013, 29, 519-524.	2.4	60
61	Apolipoprotein E Polymorphisms and Concentration in Chronic Diseases and Drug Responses. Clinical Chemistry and Laboratory Medicine, 2000, 38, 841-852.	2.3	58
62	Six Novel Loci Associated with Circulating VEGF Levels Identified by a Meta-analysis of Genome-Wide Association Studies. PLoS Genetics, 2016, 12, e1005874.	3.5	56
63	Biological Determinants of and Reference Values for Plasma Interleukin-8, Monocyte Chemoattractant Protein-1, Epidermal Growth Factor, and Vascular Endothelial Growth Factor: Results from the STANISLAS Cohort. Clinical Chemistry, 2006, 52, 504-510.	3.2	55
64	Peripheral blood mononuclear cells (PBMCs): a possible model for studying cardiovascular biology systems. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1154-68.	2.3	55
65	DNA polymorphisms of the apoprotein B gene are associated with altered plasma lipoprotein concentrations but not with perceived risk of cardiovascular disease: European Atherosclerosis Research Study. Atherosclerosis, 1995, 116, 221-234.	0.8	54
66	Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease. Journal of the Neurological Sciences, 1997, 145, 33-39.	0.6	54
67	The association of telomere length with paternal history of premature myocardial infarction in the European Atherosclerosis Research Study II. Journal of Molecular Medicine, 2008, 86, 815-824.	3.9	54
68	Apolipoprotein E-∈A allele and Alzheimer's disease. Lancet, The, 1993, 342, 1308-1309.	13.7	51
69	Apolipoprotein E4, lipoprotein lipase C447 and angiotensin-I converting enzyme deletion alleles were not associated with increased wall thickness of carotid and femoral arteries in healthy subjects from the Stanislas cohort. Atherosclerosis, 1998, 140, 89-95.	0.8	51
70	High Prevalence of Metabolic Syndrome in Iran in Comparison with France: What Are the Components That Explain This?. Metabolic Syndrome and Related Disorders, 2012, 10, 181-188.	1.3	51
71	The STANISLAS Cohort: a 10-year follow-up of supposed healthy families. Gene-environment interactions, reference values and evaluation of biomarkers in prevention of cardiovascular diseases. Clinical Chemistry and Laboratory Medicine, 2008, 46, 733-47.	2.3	50
72	Genetic and Environmental Influences on Left Ventricular Mass. Hypertension, 2000, 36, 740-746.	2.7	48

#	Article	IF	Citations
73	Public Biobanks: Calculation and Recovery of Costs. Science Translational Medicine, 2014, 6, 261fs45.	12.4	47
74	Multivariate genetic analysis of high density lipoprotein particles. Atherosclerosis, 1992, 92, 219-227.	0.8	46
75	DNA Extraction and Stability for Epidemiological Studies. Clinical Chemistry and Laboratory Medicine, 1998, 36, 551-5.	2.3	46
76	Genetic variants predisposing to cardiovascular disease. Current Opinion in Lipidology, 2006, 17, 139-151.	2.7	46
77	A Multilocus Genotyping Assay for Cardiovascular Disease. Clinical Chemistry and Laboratory Medicine, 1998, 36, 561-6.	2.3	45
78	National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. International Journal of Epidemiology, 2020, 49, 173-192.	1.9	44
79	Association of apolipoprotein E allele Ïµ4 with lateâ€onset sporadic Alzheimer's disease. American Journal of Medical Genetics Part A, 1994, 54, 286-288.	2.4	43
80	Effect of apo E phenotype on plasma postprandial triglyceride levels in young male adults with and without a familial history of myocardial infarction: the EARS II study. Atherosclerosis, 1999, 145, 381-388.	0.8	42
81	Myeloperoxidase polymorphisms in brain infarction. Association with infarct size and functional outcome. Atherosclerosis, 2003, 167, 223-230.	0.8	42
82	A multiâ€stage multiâ€design strategy provides strong evidence that the BAI3 locus is associated with earlyâ€onset venous thromboembolism. Journal of Thrombosis and Haemostasis, 2010, 8, 2671-2679.	3.8	42
83	Association of TERC and OBFC1 Haplotypes with Mean Leukocyte Telomere Length and Risk for Coronary Heart Disease. PLoS ONE, 2013, 8, e83122.	2.5	42
84	Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. ELife, 2021, 10, .	6.0	41
85	Extension of variance components approach to incorporate temporal trends and longitudinal pedigree data analysis. Genetic Epidemiology, 2002, 22, 221-232.	1.3	40
86	Enzymes and pharmacogenetics of cardiovascular drugs. Clinica Chimica Acta, 2007, 381, 26-31.	1.1	40
87	Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population. Fundamental and Clinical Pharmacology, 2007, 21, 411-418.	1.9	40
88	Two polymorphisms for amino acid substitutions in the APOA4 gene. Nucleic Acids Research, 1990, 18, 4966-4966.	14.5	38
89	Visfatin, lowâ€grade inflammation and body mass index (BMI). Clinical Endocrinology, 2008, 69, 568-574.	2.4	38
90	The effect of variation in the apolipoprotein B gene on plasma lipid and apolipoprotein B levels I. A likelihoodâ€based approach to cladistic analysis. Annals of Human Genetics, 1994, 58, 35-64.	0.8	37

#	Article	IF	Citations
91	Collection and Storage of Human Blood Cells for mRNA Expression Profiling: A 15-Month Stability Study. Clinical Chemistry, 2005, 51, 1250-1252.	3.2	37
92	Compared Effect of Immunosuppressive Drugs Cyclosporine A and Rapamycin on Cholesterol Homeostasis Key Enzymes CYP27A1 and HMG-CoA Reductase. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 392-397.	2.5	37
93	Substantial variation in qPCR measured mean blood telomere lengths in young men from eleven European countries. American Journal of Human Biology, 2011, 23, 228-231.	1.6	37
94	Novel association approach for variable number tandem repeats (VNTRs) identifies DOCK5 as a susceptibility gene for severe obesity. Human Molecular Genetics, 2012, 21, 3727-3738.	2.9	37
95	Systematic analysis of serum lipoproteins and apolipoproteins by a combined technique of micro two-dimensional electrophoresis. Electrophoresis, 1987, 8, 325-330.	2.4	35
96	Association between Gly241Arg ICAM-1 gene polymorphism and serum sICAM-1 concentration in the Stanislas cohort. European Journal of Human Genetics, 2003, 11, 679-686.	2.8	35
97	Myeloperoxidase G-463A polymorphism and Alzheimer's disease in the ApoEurope study. Neuroscience Letters, 2003, 349, 95-98.	2.1	35
98	Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. Pharmacogenomics Journal, 2005, 5, 271-275.	2.0	35
99	Genetic Polymorphism of CYP2C19 Gene in the Stanislas Cohort. A link with Inflammation. Annals of Human Genetics, 2008, 72, 178-183.	0.8	35
100	What Is the Contribution of Two Genetic Variants Regulating VEGF Levels to Type 2 Diabetes Risk and to Microvascular Complications?. PLoS ONE, 2013, 8, e55921.	2.5	35
101	VEGF-related polymorphisms identified by GWAS and risk for major depression. Translational Psychiatry, 2017, 7, e1055-e1055.	4.8	34
102	A Genome-Wide Association Study Identifies rs2000999 as a Strong Genetic Determinant of Circulating Haptoglobin Levels. PLoS ONE, 2012, 7, e32327.	2.5	34
103	Changes in Serum Retinol, Î±-Tocopherol, Vitamin C, Carotenoids, Zinc and Selenium after Micronutrient Supplementation during Alcohol Rehabilitation. Journal of the American College of Nutrition, 2003, 22, 303-310.	1.8	33
104	Serum Total Antioxidant Status, Erythrocyte Superoxide Dismutase and Whole-Blood Glutathione Peroxidase Activities in the Stanislas Cohort: Influencing Factors and Reference Intervals. Clinical Chemistry and Laboratory Medicine, 2003, 41, 209-15.	2.3	33
105	Heritability for Plasma VEGF Concentration in the Stanislas Family Study. Annals of Human Genetics, 2007, 71, 54-63.	0.8	33
106	The future of telomere length in personalized medicine. Frontiers in Bioscience - Landmark, 2018, 23, 1628-1654.	3.0	33
107	Telomere length determinants in childhood. Clinical Chemistry and Laboratory Medicine, 2020, 58, 162-177.	2.3	33
108	Pharmacogenomics and drug response in cardiovascular disorders. Pharmacogenomics, 2004, 5, 779-802.	1.3	32

#	Article	IF	Citations
109	Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. European Journal of Pharmacology, 2005, 527, 1-22.	3.5	32
110	A Prospective Study on the Prevalence of Metabolic Syndrome Among Healthy French Families: Two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-Â) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care, 2005, 28, 675-682.	8.6	32
111	Genetic biomarkers of hypertension and future challenges integrating epigenomics. Clinica Chimica Acta, 2012, 414, 259-265.	1.1	32
112	Genome-wide association study of circulating interleukin 6 levels identifies novel loci. Human Molecular Genetics, 2021, 30, 393-409.	2.9	32
113	TREM-1 SNP rs2234246 regulates TREM-1 protein and mRNA levels and is associated with plasma levels of L-selectin. PLoS ONE, 2017, 12, e0182226.	2.5	31
114	Polymorphism of the 5-HT2A receptor gene and food intakes in children and adolescents: the Stanislas Family Study. American Journal of Clinical Nutrition, 2005, 82, 467-470.	4.7	30
115	VEGF, the underlying factor for metabolic syndrome; fact or fiction?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S61-S64.	3.6	30
116	APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas Cohort). Clinical Genetics, 2001, 59, 316-324.	2.0	29
117	The Lipoprotein Lipase Serine 447 Stop Polymorphism Is Associated With Altered Serum Carotenoid Concentrations in the Stanislas Family Study. Journal of the American College of Nutrition, 2007, 26, 655-662.	1.8	29
118	Apolipoprotein E Activates Akt Pathway in Neuro-2a in an Isoform-Specific Manner. Biochemical and Biophysical Research Communications, 2002, 292, 83-87.	2.1	28
119	Synthesis and in Vitro Antioxidant Activity of Glycyrrhetinic Acid Derivatives Tested with the Cytochrome P450/NADPH System. Chemical and Pharmaceutical Bulletin, 2004, 52, 1436-1439.	1.3	28
120	Association of human cathelicidin (hCAP-18/LL-37) gene expression with cardiovascular disease risk factors. Nutrition, Metabolism and Cardiovascular Diseases, 2009, 19, 720-728.	2.6	28
121	A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. Journal of Lipid Research, 2013, 54, 535-541.	4.2	28
122	Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas Cohort. Journal of Lipid Research, 2003, 44, 430-436.	4.2	27
123	The Leu554Phe polymorphism in the E-selectin gene is associated with blood pressure in overweight people. Journal of Hypertension, 2004, 22, 305-311.	0.5	27
124	Five-year alterations in BMI are associated with clustering of changes in cardiovascular risk factors in a gender-dependant way: the Stanislas study. International Journal of Obesity, 2008, 32, 1279-1288.	3.4	27
125	Angiogenesis related genes NOS3, CD14, MMP3 and IL4R are associated to VEGF gene expression and circulating levels in healthy adults. BMC Medical Genetics, 2015, 16, 90.	2.1	27
126	Ethnic differences in the linkage disequilibrium and distribution of single-nucleotide polymorphisms in 35 candidate genes for cardiovascular diseases. Genomics, 2004, 83, 559-565.	2.9	26

#	Article	IF	Citations
127	Frequencies of five genetic polymorphisms in coronarographed patients and effects on lipid levels in a supposedly healthy population. Clinical Genetics, 1996, 50, 339-347.	2.0	26
128	PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study. Clinical Chemistry and Laboratory Medicine, 2003, 41, 535-40.	2.3	25
129	Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane receptor genes in response to cocaine in human U373 MG astrocytoma cells. Toxicology Letters, 2005, 159, 203-211.	0.8	25
130	Lipoprotein lipase (C/G)447 polymorphism and blood pressure in the Stanislas Cohort. Journal of Hypertension, 2000, 18, 1775-1781.	0.5	24
131	Sexâ€dependent Associations of Leptin With Metabolic Syndromeâ€"related Variables: The Stanislas Study. Obesity, 2010, 18, 196-201.	3.0	24
132	Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine, 2013, 61, 602-607.	3.2	24
133	Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids. Drug Metabolism Reviews, 2014, 46, 33-56.	3.6	24
134	Apolipoprotein E genotype ?4/?2 in the STANISLAS Cohort Study - Dominance of the ?2 allele ?. Annals of Human Genetics, 1996, 60, 509-516.	0.8	23
135	Age- and Sex-related Reference Values for Serum Adhesion Molecule Concentrations in Healthy Individuals: Intercellular Adhesion Molecule-1 and E-, P-, and L-Selectin. Clinical Chemistry, 2003, 49, 1544-1546.	3.2	23
136	Effect of HMGCoA Reductase Inhibitors on Cytochrome P450 Expression in Endothelial Cell Line. Journal of Cardiovascular Pharmacology, 2007, 49, 306-315.	1.9	23
137	Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clinica Chimica Acta, 2009, 403, 198-202.	1.1	23
138	Expression of inflammatory molecules and associations with BMI in children. European Journal of Clinical Investigation, 2010, 40, 388-392.	3.4	23
139	A Parametric Copula Model for Analysis of Familial Binary Data. American Journal of Human Genetics, 1999, 64, 886-893.	6.2	22
140	Family study of the relationship between height and cardiovascular risk factors in the STANISLAS cohort. International Journal of Epidemiology, 2003, 32, 607-614.	1.9	22
141	Cardiovascular diseases and genome-wide association studies. Clinica Chimica Acta, 2011, 412, 1697-1701.	1.1	22
142	Interaction between CYP1A1 T3801C and AHR G1661A polymorphisms according to smoking status on blood pressure in the Stanislas cohort. Journal of Hypertension, 2006, 24, 2199-2205.	0.5	21
143	Alcohol Consumption, Beverage Preference, and Diet in Middle-Aged Men from the STANISLAS Study. Journal of Nutrition and Metabolism, 2012, 2012, 1-6.	1.8	21
144	Visfatin: The Link Between Inflammation and Childhood Obesity. Diabetes Care, 2009, 32, e71-e71.	8.6	20

#	Article	IF	Citations
145	Biological factors affecting concentrations of serum LpAI lipoprotein particles in serum, and determination of reference limits. Clinical Chemistry, 1990, 36, 677-680.	3.2	19
146	Apo B signal peptide insertion/deletion polymorphism is involved in postprandial lipoparticles' responses. Atherosclerosis, 1995, 118, 23-34.	0.8	19
147	Conformation of apolipoprotein E both in free and in lipid-bound form may determine the avidity of triglyceride-rich lipoproteins to the LDL receptor: structural and kinetic study. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1484, 14-28.	2.4	19
148	Klotho KL-VS genotype is involved in blood pressure regulation. Clinica Chimica Acta, 2011, 412, 1773-1777.	1.1	19
149	Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. Molecular Nutrition and Food Research, 2021, 65, e2001178.	3.3	19
150	Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clinical and Experimental Medicine, 2005, 5, 196-201.	3.6	18
151	Apolipoprotein AIV codon 360 mutation increases with human aging and is not associated with Alzheimer's disease. Neuroscience Letters, 1998, 242, 117-119.	2.1	17
152	CYTOCHROMES P450 ARE DIFFERENTLY EXPRESSED IN NORMAL AND VARICOSE HUMAN SAPHENOUS VEINS: LINKAGE WITH VARICOSIS. Clinical and Experimental Pharmacology and Physiology, 2004, 31, 295-301.	1.9	17
153	Inter-individual variation of inflammatory markers of cardiovascular risks and diseases. Clinical Chemistry and Laboratory Medicine, 2005, 43, 671-84.	2.3	17
154	Association Between Angiotensin II Type 1 Receptor Gene Polymorphism andÂMetabolic Syndrome in a Young Female Iranian Population. Archives of Medical Research, 2010, 41, 343-349.	3.3	17
155	Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS). International Journal of Molecular Sciences, 2019, 20, 1014.	4.1	17
156	Milestones in Personalized Medicine: From the Ancient Time to Nowadaysâ€"the Provocation of COVID-19. Frontiers in Genetics, 2020, 11, 569175.	2.3	17
157	Familial resemblance of plasma apolipoprotein B: The Nancy study. Genetic Epidemiology, 1990, 7, 187-197.	1.3	16
158	A Comparison of Lifestyle, Genetic, Bioclinical and Biochemical Variables of Offspring with and without Family Histories of Premature Coronary Heart Disease: The Experience of the European Atherosclerosis Research Studies. European Journal of Cardiovascular Prevention and Rehabilitation, 1999, 6, 183-188.	2.8	15
159	Familial Studies on the Genetics of Cardiovascular Diseases: the Stanislas Cohort. Clinical Chemistry and Laboratory Medicine, 2000, 38, 827-32.	2.3	15
160	Leptin expression in Peripheral Blood Mononuclear Cells (PBMCs) is related with blood pressure variability. Clinica Chimica Acta, 2008, 395, 47-50.	1.1	15
161	Influence of Pre-analytical Variables on VEGF Gene Expression and Circulating Protein Concentrations. Biopreservation and Biobanking, 2012, 10, 454-461.	1.0	15
162	Human formyl peptide receptor 1 C32T SNP interacts with age and is associated with blood pressure levels. Clinica Chimica Acta, 2012, 413, 34-38.	1.1	15

#	Article	IF	Citations
163	Clinical necessity of partitioning of human plasma haptoglobin reference intervals by recently-discovered rs2000999. Clinica Chimica Acta, 2012, 413, 1618-1624.	1.1	15
164	Candidate Gene Polymorphism in Cardiovascular Disease: A Comparative Study of Frequencies between a French and an Italian Population. Clinical Chemistry and Laboratory Medicine, 2001, 39, 146-54.	2.3	14
165	Effect of six candidate genes on early aging in a French population. Aging Clinical and Experimental Research, 2003, 15, 111-116.	2.9	14
166	Pharmacogenomics of Drugs Affecting the Cardiovascular System. Clinical Chemistry and Laboratory Medicine, 2003, 41, 590-9.	2.3	14
167	Metabolic syndrome-related composite factors over 5years in the STANISLAS Family Study: Genetic heritability and common environmental influences. Clinica Chimica Acta, 2010, 411, 833-839.	1.1	14
168	Relationship between catalase haplotype and arterial aging. Atherosclerosis, 2013, 227, 100-105.	0.8	14
169	VEGF-A is associated with early degenerative changes in cartilage and subchondral bone. Growth Factors, 2018, 36, 263-273.	1.7	14
170	Genetic determinants of circulating haptoglobin concentration. Clinica Chimica Acta, 2019, 494, 138-142.	1.1	14
171	Environmental And Genetic Determinants Of Intima-Media Thickness Of The Carotid Artery. Clinical and Experimental Pharmacology and Physiology, 2001, 28, 1007-1010.	1.9	13
172	Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. Atherosclerosis, 2007, 191, 369-376.	0.8	13
173	Epistatic study reveals two genetic interactions in blood pressure regulation. BMC Medical Genetics, 2013, 14, 2.	2.1	13
174	Signal peptide-length variation in human apolipoprotein B gene. Molecular characteristics and association with plasma glucose levels. Diabetes, 1991, 40, 1539-1544.	0.6	13
175	Apolipoproteins E and C-III in apo B- and non-apo B-containing lipoproteins in middle-aged women from the Stanislas cohort: effect of oral contraceptive use and common apolipoprotein E polymorphism. Atherosclerosis, 2001, 155, 509-516.	0.8	12
176	Age- and sex-related reference values for serum insulin concentration and its biological determinants in a French healthy population. The STANISLAS cohort. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1140-9.	2.3	12
177	Effect of acute and chronic psychostimulant drugs on redox status, AP-1 activation and pro-enkephalin mRNA in the human astrocyte-like U373 MG cells. Neuropharmacology, 2005, 48, 673-684.	4.1	12
178	Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia. Journal of Clinical Laboratory Analysis, 2006, 20, 98-104.	2.1	12
179	Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases. Current Pharmaceutical Design, 2009, 15, 3193-3206.	1.9	12
180	Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-Inflammatory Status in Mastiha-Supplemented Patients With NAFLD. Frontiers in Immunology, 2021, 12, 683028.	4.8	12

#	Article	IF	Citations
181	Two-dimensional electrophoresis of plasma proteins and high density lipoproteins during inflammation. Electrophoresis, 1989, 10, 781-784.	2.4	11
182	Sources of variability of human plasma apolipoprotein A-IV levels and relationships with lipid metabolism. Genetic Epidemiology, 1994, 11, 101-114.	1.3	11
183	Associations of Apolipoprotein E Concentration and Polymorphism with Lipids and Apolipoprotein Levels in Chinese from Beijing and Shanghai. Clinical Chemistry and Laboratory Medicine, 2000, 38, 655-9.	2.3	11
184	Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2000, 1484, 29-40.	2.4	11
185	Proteinâ€“lipid interactions in reconstituted high density lipoproteins: apolipoprotein and cholesterol influence. Chemistry and Physics of Lipids, 2001, 113, 67-82.	3.2	11
186	The composition, structural properties and binding of very-low-density and low-density lipoproteins to the LDL receptor in normo- and hypertriglyceridemia: relation to the apolipoprotein E phenotype. Biological Chemistry, 2005, 386, 441-52.	2.5	11
187	Association of classical and related inflammatory markers with high-sensitivity C-reactive protein in healthy individuals: results from the Stanislas cohort. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1339-46.	2.3	11
188	Association between TNF and IL-1 bloc polymorphisms and plasma MCP-1 concentration. Atherosclerosis, 2007, 192, 348-353.	0.8	11
189	Association Study of Gene Polymorphisms Involved in Vascular Alterations in Elderly Hypertensives with Subjective Memory Complaints. Dementia and Geriatric Cognitive Disorders, 2010, 30, 440-448.	1.5	11
190	Effects of apo B and apo E gene polymorphisms on lipid and apolipoprotein concentrations after a test meal. Clinica Chimica Acta, 1996, 253, 127-143.	1.1	10
191	Association of Apolipoprotein E Polymorphism and Concentration with Serum Lipids and Apo-lipoprotein Level in the Chinese fromShanghai. Clinical Chemistry and Laboratory Medicine, 1998, 36, 615-619.	2.3	10
192	Apolipoprotein E in Apolipoprotein B (apo B)- and Non-apo B-containing Lipoproteins in 3523 Participants in the Stanislas Cohort: Biological Variation and Genotype-specific Reference Limits. Clinical Chemistry, 2002, 48, 291-300.	3.2	10
193	Charge-based heterogeneity of human plasma lipoproteins at hypertriglyceridemia: capillary isotachophoresis study. International Journal of Biochemistry and Cell Biology, 2003, 35, 530-543.	2.8	10
194	Different Genes and Polymorphisms Affecting High-Density Lipoprotein Cholesterol Levels in Greek Familial Hypercholesterolemia Patients. Genetic Testing and Molecular Biomarkers, 2006, 10, 192-199.	1.7	10
195	Heritability of serum hs-CRP concentration and 5-year changes in the Stanislas family study: association with apolipoprotein E alleles. Genes and Immunity, 2007, 8, 352-359.	4.1	10
196	Statins as effectors of key activities involved in apoE-dependent VLDL metabolism: Review and hypothesis. Vascular Pharmacology, 2008, 48, 70-75.	2.1	10
197	Genetic Determinants of Leucocyte Telomere Length in Children: a Neglected and Challenging Field. Paediatric and Perinatal Epidemiology, 2015, 29, 146-150.	1.7	10
198	VEGF-A-related genetic variants protect against Alzheimerâ€™s disease. Aging, 2022, 14, 2524-2536.	3.1	10

#	Article	IF	Citations
199	Letter to the Editor: High-resolution separation of PCR product and gene diagnosis by capillary gel electrophoresis. , 1996, 10, 48-50.		9
200	High Sensitivity of Laser-Induced Fluorescence Detection in Capillary Gel Electrophoresis for Accurate Apolipoprotein E Genotyping. BioTechniques, 1997, 22, 736-742.	1.8	9
201	Homo- and hetero-complexes of exchangeable apolipoproteins in solution and in lipid-bound form. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2003, 59, 1127-1137.	3.9	9
202	P-selectin polymorphismsâ€™ influences on P-selectin serum concentrations and on their familial correlation: the STANISLAS family study. Journal of Thrombosis and Haemostasis, 2008, 6, 920-927.	3.8	9
203	Personalized therapy and pharmacogenomics: future perspective. Pharmacogenomics, 2009, 10, 927-930.	1.3	9
204	Personalised Medicine: The Odyssey from Hope to Practice. Journal of Personalized Medicine, 2018, 8, 31.	2.5	9
205	Immunochemical study of the plasma low and high density lipoproteins in Tangier disease. FEBS Letters, 1986, 201, 163-167.	2.8	8
206	Lipid and lipoprotein genetic variability: An important contribution from the French health Examination Centers. Clinical Biochemistry, 1995, 28, 31-38.	1.9	8
207	Association Between Factor VII Polymorphisms and Blood Pressure. Hypertension, 2004, 44, 674-680.	2.7	8
208	Genetic influences on blood pressure within the Stanislas Cohort. Journal of Hypertension, 2004, 22, 297-304.	0.5	8
209	Association between EGF and lipid concentrations: A benefit role in the atherosclerotic process?. Clinica Chimica Acta, 2009, 402, 196-198.	1.1	8
210	Human formyl peptide receptor 1 (FPR1) c.32C>T SNP is associated with decreased soluble E-selectin levels. Pharmacogenomics, 2009, 10, 951-959.	1.3	8
211	Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice. Current Pharmaceutical Biotechnology, 2017, 18, 231-241.	1.6	8
212	Pleiotropy of ABO gene: correlation of rs644234 with E-selectin and lipid levels. Clinical Chemistry and Laboratory Medicine, 2018, 56, 748-754.	2.3	8
213	The Relationship Between Vascular Endothelial Growth Factor Cis- and Trans-Acting Genetic Variants and Metabolic Syndrome. American Journal of the Medical Sciences, 2018, 355, 559-565.	1.1	8
214	Functional Epistatic Interaction between rs6046G>A in F7 and rs5355C>T in SELE Modifies Systolic Blood Pressure Levels. PLoS ONE, 2012, 7, e40777.	2.5	8
215	Capillary electrophoretic analysis of recombinant human apolipoprotein E. Journal of Chromatography A, 1999, 853, 237-241.	3.7	7
216	Changes in Serum Apolipoprotein and Lipoprotein Profile After Alcohol Withdrawal: Effect of Apolipoprotein E Polymorphism. Alcoholism: Clinical and Experimental Research, 2002, 26, 501-508.	2.4	7

#	Article	IF	Citations
217	Phenotypic sensitivity to activated protein C in healthy families: importance of genetic components and environmental factors. British Journal of Haematology, 2004, 126, 392-397.	2.5	7
218	Adipokine expression in adipose tissue and in peripheral blood mononuclear cells in children. Clinica Chimica Acta, 2009, 410, 85-89.	1.1	7
219	IL6R haplotype rs4845625*T/rs4537545*C is a risk factor for simultaneously high CRP, LDL and ApoB levels. Genes and Immunity, 2017, 18, 163-169.	4.1	7
220	Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population. PLoS ONE, 2019, 14, e0220902.	2.5	7
221	Multilocus approach to cardiovascular risk. Scandinavian Journal of Clinical and Laboratory Investigation, 1999, 59, 168-176.	1.2	6
222	Time-dependent lipid response on fluvastatin therapy of patients with hypercholesterolemia sensitive to apoE phenotype. Vascular Pharmacology, 2003, 40, 237-245.	2.1	6
223	Cardiovascular risk-associated allele frequencies for 15 genes in healthy elderly French and Chinese. Clinical Chemistry and Laboratory Medicine, 2005, 43, 817-22.	2.3	6
224	Genetic profiling of human cell lines used as in vitro model to study cardiovascular pathophysiology and pharmacotoxicology. Cell Biology and Toxicology, 2009, 25, 561-571.	5.3	6
225	Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases. Autoimmunity, 2016, 49, 366-372.	2.6	6
226	Plasma VEGF-related polymorphisms are implied in autoimmune thyroid diseases. Autoimmunity, 2016, 49, 229-235.	2.6	6
227	Dietary Patterns, Blood Pressure and the Glycemic and Lipidemic Profile of Two Teenage, European Populations. Nutrients, 2021, 13, 198.	4.1	6
228	Relationship between E-selectin L/F554 polymorphism and blood pressure in the Stanislas cohort. Human Genetics, 2000, 107, 58-61.	3.8	6
229	Eâ€Selectin Genotypes and Risk of Type 2 Diabetes in Women: Genetic and Environmental Contributions to Serum Soluble Eâ€Selectin Concentrations. Obesity, 2005, 13, 1845-1847.	4.0	5
230	Candidate gene microarray analysis in peripheral blood cells for studying hypertension/obesity. Personalized Medicine, 2009, 6, 269-291.	1.5	5
231	Drug Metabolizing Enzymes and Transporters mRNA in Peripheral Blood Mononuclear Cells of Healthy Subjects: Biological Variations and Importance of Preanalytical Steps. Current Drug Metabolism, 2009, 10, 410-419.	1.2	5
232	Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin. Pharmacogenomics, 2012, 13, 1215-1218.	1.3	5
233	Cardiovascular diseases-related GNB3 C825T polymorphism has a significant sex-specific effect on serum soluble E-selectin levels. Journal of Inflammation, 2016, 13, 39.	3.4	5
234	Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug Metabolism and Personalized Therapy, 2018, 33, 41-47.	0.6	5

#	Article	IF	Citations
235	Effect of LSR polymorphism on blood lipid levels and ageâ€specific epistatic interaction with the APOE common polymorphism. Clinical Genetics, 2018, 93, 846-852.	2.0	5
236	Apolipoprotein E Level in Cerebrospinal Fluid Increases With Aging. Journal of the American Geriatrics Society, 1997, 45, 1536-1536.	2.6	4
237	Human Apolipoprotein E concentration in response to diseases and therapeutic treatments. Drug Development Research, 2002, 56, 95-110.	2.9	4
238	Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. Personalized Medicine, 2007, 4, 393-412.	1.5	4
239	A new single nucleotide polymorphism genotyping method based on gap ligase chain reaction and a microsphere detection assay. Clinical Chemistry and Laboratory Medicine, 2008, 46, 486-9.	2.3	4
240	Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy. Pharmacogenomics, 2011, 12, 681-691.	1.3	4
241	Epistatic interaction of apolipoprotein E and lipolysis-stimulated lipoprotein receptor genetic variants is associated with Alzheimer's disease. Neurobiology of Aging, 2018, 69, 292.e1-292.e5.	3.1	4
242	Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration. Clinical Epigenetics, 2020, 12, 79.	4.1	4
243	The Role of Genetics in Defining Reference Values and Health Status. Methods of Information in Medicine, 1993, 32, 255-259.	1.2	4
244	Sample size calculations for classical association and TDT-type methods using family data. Annals of Human Genetics, 2001, 65, 293-312.	0.8	3
245	Reference materials (RMs) for analysis of the human factor II (prothrombin) gene G20210A mutation. Clinical Chemistry and Laboratory Medicine, 2005, 43, 862-8.	2.3	3
246	Polymorphisms associated with apolipoprotein B levels in Greek patients with familial hypercholesterolemia. Clinical Chemistry and Laboratory Medicine, 2006, 44, 799-806.	2.3	3
247	From human genetic variations to prediction of risks and responses to drugs and the environment. Personalized Medicine, 2007, 4, 95-104.	1.5	3
248	Lack of Association between EGF 61A>G Polymorphism and Plasma EGF Concentration in the STANISLAS Family Study. Journal of Investigative Dermatology, 2007, 127, 969-970.	0.7	3
249	Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 2. ApoE and apoC-III relations in triglyceride clearance. Molecular and Cellular Biochemistry, 2009, 325, 25-40.	3.1	3
250	Capillary isotachophoresis study of lipoprotein network sensitive to apolipoprotein E phenotype. 1. ApoE distribution between lipoproteins. Molecular and Cellular Biochemistry, 2009, 325, 41-51.	3.1	3
251	Functional genomics towards personalized healthcare. Personalized Medicine, 2009, 6, 19-32.	1.5	3
252	Biological and genetic factors associated with ABCB1 and pregnane-X-receptor expressions in peripheral blood mononuclear cells in the STANISLAS cohort. Drug Metabolism and Drug Interactions, 2011, 26, 27-32.	0.3	3

#	Article	IF	Citations
253	The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-Î± levels and IMT-F. Scientific Reports, 2018, 8, 7160.	3.3	3
254	TERC Variants Associated with Short Leukocyte Telomeres: Implication of Higher Early Life Leukocyte Telomere Attrition as Assessed by the Blood-and-Muscle Model. Cells, 2020, 9, 1360.	4.1	3
255	Epigenome-wide association study detects a novel loci associated with central obesity in healthy subjects. BMC Medical Genomics, 2021, 14, 233.	1.5	3
256	Obesity status modifies the association between rs7556897T>C in the intergenic region SLC19A3-CCL20 and blood pressure in French children. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1819-1827.	2.3	3
257	Molecular Pharmacophore Determination of Lipid Lowering Drugs with the Receptor Mapping Method. Mini-Reviews in Medicinal Chemistry, 2002, 2, 97-102.	2.4	2
258	Genetic and environmental contributions to serum ascorbic acid concentrations: the Stanislas Family Study. British Journal of Nutrition, 2006, 96, 1013-1020.	2.3	2
259	Newly identified synergy between clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285. International Journal of Cardiology, 2013, 168, 3057-3058.	1.7	2
260	A genetic determinant of VEGF-A levels is associated with telomere attrition. Aging, 2021, 13, 23517-23526.	3.1	2
261	Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study. International Journal of Environmental Research and Public Health, 2022, 19, 971.	2.6	2
262	Study of the sequence tagged site (STS) in the beginning of human apo A4 gene region. Nucleic Acids Research, 1990, 18, 5576-5576.	14.5	1
263	Genetic profiling in healthy subjects from the Stanislas cohort based on 24 polymorphisms: effects on biological variables. Clinical Chemistry and Laboratory Medicine, 2008, 46, 64-72.	2.3	1
264	Functional genomics towards personalized healthcare and systems medicine. Personalized Medicine, 2011, 8, 227-242.	1.5	1
265	Common mutations and polymorphisms predicting adverse cardiovascular events: current view. Pharmacogenomics, 2012, 13, 1875-1878.	1.3	1
266	Influence of Genetic Variations on Levels of Inflammatory Markers of Healthy Subjects at Baseline and One Week after Clopidogrel Therapy; Results of a Preliminary Study. International Journal of Molecular Sciences, 2013, 14, 16402-16413.	4.1	1
267	Conference Scene: Pharmacogenomics: from cell to clinic (Part 2). Pharmacogenomics, 2014, 15, 739-744.	1.3	1
268	Next generation sequencing and immuno-histochemistry profiling identify numerous biomarkers for personalized therapy of endometrioid endometrial carcinoma. Clinical Chemistry and Laboratory Medicine, 2017, 56, e19-e22.	2.3	1
269	A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: the VEGF Consortium. Clinical Chemistry and Laboratory Medicine, 2018, 56, 83-86.	2.3	1
270	Do we need diagnostic strategies enhanced with genetic information for ischemic heart disease?. Journal of Nuclear Cardiology, 2019, 26, 1309-1312.	2.1	1

#	Article	IF	Citations
271	Increased risk of hypercholesterolemia in a French and Lebanese population due to an interaction between rs2569190 in CD14 and gender. Clinica Chimica Acta, 2020, 509, 172-176.	1.1	1
272	The association of vascular endothelial growth factor related SNPs and circulating iron levels might depend on body mass index. Frontiers in Bioscience, 2022, 27, 1.	2.1	1
273	4.P.391 Familial study of genetic determinants of carotid intima-media thickness in an healthy population. Implication of apolipoprotein E polymorphism. Atherosclerosis, 1997, 134, 379.	0.8	0
274	4.P.232 Possible competition between VLDL and LDL for the binding to LDL receptor at hypertriglyceridemia - an in vitro estimate. Atherosclerosis, 1997, 134, 344.	0.8	0
275	1.P.326 Effect of apoE phenotype on postprandial triglycerides levels in young male with and without a familial history of myocardial infarction: The EARS II study. Atherosclerosis, 1997, 134, 85.	0.8	0
276	1.P.352 The Stanislas Cohort. A familial and longitudinal study for cardiovascular risks evaluation. Atherosclerosis, 1997, 134, 91.	0.8	0
277	3.P.128 Individual and familial determinants of autoantibodies against oxidized low density lipoprotein (oLAb). Atherosclerosis, 1997, 134, 225.	0.8	0
278	Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?. Clinical Chemistry and Laboratory Medicine, 2003, 41, 554-8.	2.3	0
279	M.581 The LEU554PHE polymorphism in the E-selectin gene is associated with blood pressure in overweight people. Atherosclerosis Supplements, 2004, 5, 135.	1.2	0
280	Th-P15:66 Changes in lipid and apolipoprotein E distribution induced by lipoprotein lipolysis in vivo in hypertriglyceridemia. Atherosclerosis Supplements, 2006, 7, 507.	1.2	0
281	Pharmacogenomics and Cardiovascular Drugs. Methods in Pharmacology and Toxicology, 2008, , 413-446.	0.2	0
282	Parental precocious influences on offspring cardiovascular risk markers: an exploratory study in the STANISLAS Cohort. Personalized Medicine, 2009, 6, 343-352.	1.5	0
283	MS64 CAPILLARY ISOTACHOPHORESIS AS AN OVERALL TOOL TO REVEAL ATHEROGENIC LIPOPROTEIN PHENOTYPE. Atherosclerosis Supplements, 2010, 11, 123.	1.2	0
284	Need for pharmacogenomic information also for generic medications: Recommendation of the European Society of Pharmacogenomics and Theranostics (ESPT). Drug Metabolism and Drug Interactions, 2012, 27, 119.	0.3	0
285	Beyond genome-wide association studies: identifying variants using -omics approaches. Personalized Medicine, 2015, 12, 529-531.	1.5	0
286	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. Pharmacogenomics, 2015, 16, 459-469.	1.3	0
287	Integrating polymorphism signatures with myocardial perfusion imaging data to improve the prevention of coronary artery disease: Science or science-fiction?. Journal of Nuclear Cardiology, 2022, 29, 2917-2919.	2.1	0
288	De lâ€™Ã©cogÃ©nÃ©tique Ã la pharmacogÃ©nomique par le stress oxydant. HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2016, NÂ° 2, 217a-218.	0.0	0

#	Article	IF	Citations
289	Le Professeur GÃ©rard Siest nous a quittÃ©s (1936-2016). HEGEL - HEpato-GastroEntÃ©rologie LibÃ©rale, 2016, NÂ° 2, 96-97.	0.0	0
290	Family study of lipoprotein lipase gene polymorphisms and plasma triglyceride levels. Genetic Epidemiology, 1996, 13, 179-192.	1.3	0